Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The road to resistance: EGFR mutation and cetuximab

Nature Medicine volume 18, pages199–200(2012)Cite this article

Subjects

Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221–223).

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

Figure 1: Cetuximab sensitivity and resistance.

References

  1. 1

    Montagut, C. et al. Nat. Med. 18, 221–223 (2012).

    CAS  Article  Google Scholar 

  2. 2

    Jonker, D.J. et al. N. Engl. J. Med. 357, 2040–2048 (2007).

    CAS  Article  Google Scholar 

  3. 3

    Vermorken, J.B. et al. N. Engl. J. Med. 359, 1116–1127 (2008).

    CAS  Article  Google Scholar 

  4. 4

    Karapetis, C.S. et al. N. Engl. J. Med. 359, 1757–1765 (2008).

    CAS  Article  Google Scholar 

  5. 5

    De Roock, W. et al. Lancet Oncol. 11, 753–762 (2010).

    CAS  Article  Google Scholar 

  6. 6

    Amado, R.G. et al. J. Clin. Oncol. 26, 1626–1634 (2008).

    CAS  Article  Google Scholar 

  7. 7

    Bardelli, A. & Siena, S. J. Clin. Oncol. 28, 1254–1261 (2010).

    CAS  Article  Google Scholar 

  8. 8

    Wadlow, R.C. et al. Oncologist published online, 10.1634/theoncologist.2011-0452 (30 December 2011).

  9. 9

    Jänne, P.A., Gray, N. & Settleman, J. Nat. Rev. Drug Discov. 8, 709–723 (2009).

    Article  Google Scholar 

  10. 10

    Yonesaka, K. et al. Sci. Transl. Med. 3, 99ra86 (2011).

    Article  Google Scholar 

  11. 11

    Bertotti, A. et al. Cancer Discov. 1, 509–523 (2011).

    Article  Google Scholar 

  12. 12

    Benavente, S. et al. Clin. Cancer Res. 15, 1585–1592 (2009).

    CAS  Article  Google Scholar 

  13. 13

    Li, C., Iida, M., Dunn, E.F., Ghia, A.J. & Wheeler, D.L. Oncogene 28, 3801–3813 (2009).

    CAS  Article  Google Scholar 

  14. 14

    Lu, Y. et al. Cancer Res. 67, 8240–8247 (2007).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Alberto Bardelli is at the Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Turin Medical School, Turin, Italy.

    Alberto Bardelli

  2. Pasi A. Jänne is at the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

    Pasi A Jänne

Authors
  1. Alberto Bardelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pasi A Jänne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pasi A Jänne.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bardelli, A., Jänne, P. The road to resistance: EGFR mutation and cetuximab. Nat Med 18, 199–200 (2012). https://doi.org/10.1038/nm.2646

Download citation

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing